Nov. 29, 2019 |
|
Feb. 22, 2024 |
|
jRCTs051190076 |
Clinical safety and efficacy of neo-adjuvant combination chemotherapy of Tranilast in advanced esophageal squamous cell carcinoma: phase I/II study (TNAC) |
|
Neo-adjuvant combination chemotherapy of Tranilast in esophageal carcinoma (TNAC) |
Shiozaki Atsushi |
||
University Hospital Kyoto prefectural University of Medicine |
||
465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, JAPAN. |
||
+81-752515527 |
||
shiozaki@koto.kpu-m.ac.jp |
||
Kudou Michihiro |
||
University Hospital Kyoto prefectural University of Medicine |
||
465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, JAPAN. |
||
+81-752515527 |
||
posit@koto.kpu-m.ac.jp |
Recruiting |
Nov. 14, 2019 |
||
59 | ||
Interventional |
||
single arm study |
||
open(masking not used) |
||
uncontrolled control |
||
single assignment |
||
treatment purpose |
||
1) Pathologically proven esophageal squamous cell carcinoma |
||
1) A history of chemotherapy or radiotherapy 1 year before treatment begins |
||
20age old over | ||
74age old under | ||
Both |
||
advanced esophageal squamous cell carcinoma |
||
The additional use of tranilast to conventional neoadjuvant chemotherapy (5-FU/CDDP) for advanced esophageal squamous cell carcinoma patients |
||
Esophageal Squamous Cell Carcinoma |
||
Esophageal Squamous Cell Carcinoma |
||
Pathological therapeutic effect |
||
clinical safety, therapeutic response diagnosed by imaging examination, down staging, ontological outcomes, |
Kyoto Prefectural University of Medicine, Clinical Research Review Board | |
465 Kajii-cho, Kamigyo-ku Kyoto 6028566 JAPAN, Kyoto | |
+81-75-251-5337 |
|
rinri@koto.kpu-m.ac.jp | |
Approval | |
Aug. 30, 2019 |
Yes |
|
none |